NASDAQ:EVOK Evoke Pharma (EVOK) Stock Price, News & Analysis $3.18 -0.28 (-8.06%) As of 12:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Evoke Pharma Stock (NASDAQ:EVOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evoke Pharma alerts:Sign Up Key Stats Today's Range$3.33▼$3.6350-Day Range$2.07▼$3.8252-Week Range$1.94▼$12.32Volume6,385 shsAverage Volume123,102 shsMarket Capitalization$4.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Read More… Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address EVOK Stock News HeadlinesEvoke Pharma Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comEvoke Pharma Announces Presentation of New Research on Tardive Dyskinesia at Digestive Disease Week 2025April 30, 2025 | nasdaq.comTrump’s Strange “Midnight Tweet” Could Trigger Massive GainsPresident Trump sends out explosive tweets at all hours of the day... And the market reacts violently. According to one Wall Street legend, Americans can target as much as 627% within HOURS. You have to see how to target these massive profits (from Trump’s latest tweets) for yourself....June 6, 2025 | Monument Traders Alliance (Ad)Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025April 28, 2025 | globenewswire.comEvoke Pharma, Inc. (NASDAQ:EVOK) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 16, 2025 | uk.finance.yahoo.comEarnings call transcript: Evoke Pharma Q4 2024 reports strong sales growthMarch 15, 2025 | uk.investing.comQ4 2024 Evoke Pharma Inc Earnings CallMarch 14, 2025 | finance.yahoo.comEvoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comSee More Headlines EVOK Stock Analysis - Frequently Asked Questions How have EVOK shares performed this year? Evoke Pharma's stock was trading at $4.42 at the start of the year. Since then, EVOK stock has decreased by 28.0% and is now trading at $3.1810. View the best growth stocks for 2025 here. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) released its quarterly earnings results on Monday, May, 12th. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.18. The specialty pharmaceutical company earned $3.08 million during the quarter, compared to the consensus estimate of $3.32 million. Evoke Pharma had a negative trailing twelve-month return on equity of 308.49% and a negative net margin of 71.32%. When did Evoke Pharma's stock split? Shares of Evoke Pharma reverse split on Thursday, August 1st 2024. The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings5/12/2025Today6/06/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVOK CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.79 million Net Margins-71.32% Pretax Margin-71.32% Return on Equity-308.49% Return on Assets-53.66% Debt Debt-to-Equity RatioN/A Current Ratio1.44 Quick Ratio1.39 Sales & Book Value Annual Sales$11.59 million Price / Sales0.45 Cash FlowN/A Price / Cash FlowN/A Book Value($9.26) per share Price / Book-0.37Miscellaneous Outstanding Shares1,493,000Free Float1,395,000Market Cap$5.17 million OptionableNot Optionable Beta0.16 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:EVOK) was last updated on 6/6/2025 by MarketBeat.com Staff From Our PartnersWhy hasn't Elon tweeted about this?Behind the scenes, there's an entirely different Tesla story brewing… . It's about a quiet stream of income...Investors Alley | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Wealth Reset: Could You Be The First Beneficiary?Trump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow to target 627% gains from Trump’s tweetsPresident Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has...Monument Traders Alliance | SponsoredThe Age of Chaos has begunThis is one of the most confusing markets in history. We have entered an Age of Chaos. And you must take...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.